SKC Formally Appeals NICE Decision

The National Institute for Health and Care Excellence (NICE) heard an appeal led by Solving Kids’ Cancer (SKC) against its recent decision to deny children in the UK treatment that is proven to significantly increase the chance of survival for children diagnosed with an aggressive childhood cancer, neuroblastoma.

Read More

Access to Cures Should Have No Borders

The British healthcare system has rejected an FDA/EMA-approved treatment proven to increase survival rates for children with cancer.  NICE (National Institute for Health and Care Excellence) has rejected access to the drug across the UK, stating cost as the reason.  However, when analyzing the real expense on taxpayers, the cost amounts to less than 3 pence per person, per year, in order to give these children access to the life-saving antibody.

Read More

The Promise of Immunotherapy

Immunotherapy is changing the paradigm for children with cancer. Solving Kids’ Cancer has teamed up with the same researchers who helped save Emily Whitehead’s life to bring a new treatment option for children with neuroblastoma. Meet one family that was on a Solving Kids’ Cancer clinical trial at the Children’s Hospital of Philadelphia

Read More

Solving Kids’ Cancer Nifurtimox trial: Meet one Family

Jordyn being diagnosed at 6 months old with neuroblastoma was a devastating shock for her mother, Jodie. After 6 ineffective rounds of chemotherapy, radiation, and surgery Jodie was left without any options, which in turn lead her to an experimental clinical trial sponsored by Solving Kids’ Cancer. This is the story of their journey to save Jordyn.

Read More

Searching for a Solution: An SKC Feature

Al Jazeera America covered the story of Solving Kids’ Cancer’s co-founders, Scott Kennedy & John London, and why they created the organization. Listen in on their stories and the inspiration behind the making of Solving Kids’ Cancer.

Read More

Challenging the Status Quo

“Solving Kids’ Cancer and the TDI offer the opportunity to develop a much more facile system for drug development.” – Dr. Kenneth Cohen from the Sidney Kimmel Cancer Center at John Hopkins University

Read More